Aspirin in Hepatocellular Carcinoma

Area of Science:

• Oncology
• Gastroenterology
• Preventative Medicine

Background:

• Aspirin is investigated for its potential cancer-preventive properties.
• Evidence suggests benefits in colorectal cancer (CRC) for Lynch syndrome and sporadic cases.
• Emerging data indicate a role in hepatocellular carcinoma (HCC) prevention and treatment.

Purpose of the Study:

• To review the evidence for aspirin's chemopreventive and adjuvant therapeutic effects in various cancers.
• To specifically examine aspirin's role in hepatocellular carcinoma (HCC) prevention and recurrence reduction.
• To explore the potential mechanisms behind aspirin's anti-cancer activities.

Main Methods:

• Review of preclinical and clinical studies, including retrospective cohort studies and epidemiological research.
• Analysis of data from animal models to understand aspirin's mechanisms of action.
• Evaluation of existing literature on aspirin use in high-risk populations and the general population.

Main Results:

• Strong evidence supports aspirin's chemopreventive effect in Lynch syndrome-associated CRC.
• Indirect evidence suggests aspirin reduces risk and mortality in sporadic CRC.
• Consistent findings show aspirin's benefit in HCC chemoprevention and as an adjuvant therapy, reducing incidence and recurrence.

Conclusions:

• Aspirin demonstrates a beneficial role in preventing and treating specific cancers, notably CRC and HCC.
• Antiplatelet and anti-inflammatory activities are proposed mechanisms for aspirin's cancer-preventive effects.
• Prospective studies are essential to establish aspirin recommendations for diverse HCC patient populations.